vs
Side-by-side financial comparison of RHYTHM PHARMACEUTICALS, INC. (RYTM) and Sila Realty Trust, Inc. (SILA). Click either name above to swap in a different company.
RHYTHM PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($57.3M vs $50.1M, roughly 1.1× Sila Realty Trust, Inc.). Sila Realty Trust, Inc. runs the higher net margin — 10.0% vs -83.0%, a 93.0% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs 7.6%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs -0.6%).
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
Sila Realty Trust, Inc. is a U.S.-based real estate investment trust that owns, operates, and acquires high-quality income-generating commercial properties. Its core portfolio covers industrial logistics facilities, office assets and mixed-use properties, serving tenants across logistics, corporate and retail segments to deliver stable long-term returns.
RYTM vs SILA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $57.3M | $50.1M |
| Net Profit | $-47.5M | $5.0M |
| Gross Margin | 91.6% | 88.9% |
| Operating Margin | -82.2% | — |
| Net Margin | -83.0% | 10.0% |
| Revenue YoY | 36.9% | 7.6% |
| Net Profit YoY | -9.6% | -54.9% |
| EPS (diluted) | $-0.73 | $0.10 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $57.3M | $50.1M | ||
| Q3 25 | $51.3M | $49.8M | ||
| Q2 25 | $48.5M | $48.7M | ||
| Q1 25 | $32.7M | $48.3M | ||
| Q4 24 | $41.8M | $46.5M | ||
| Q3 24 | $33.3M | $46.1M | ||
| Q2 24 | $29.1M | $43.6M | ||
| Q1 24 | $26.0M | $50.6M |
| Q4 25 | $-47.5M | $5.0M | ||
| Q3 25 | $-52.9M | $11.6M | ||
| Q2 25 | $-46.6M | $8.6M | ||
| Q1 25 | $-49.5M | $7.9M | ||
| Q4 24 | $-43.3M | $11.1M | ||
| Q3 24 | $-43.6M | $11.9M | ||
| Q2 24 | $-32.3M | $4.6M | ||
| Q1 24 | $-141.4M | $15.0M |
| Q4 25 | 91.6% | 88.9% | ||
| Q3 25 | 89.3% | 88.1% | ||
| Q2 25 | 88.6% | 87.7% | ||
| Q1 25 | 88.8% | 86.9% | ||
| Q4 24 | 90.9% | 87.3% | ||
| Q3 24 | 88.5% | 87.4% | ||
| Q2 24 | 89.9% | 86.6% | ||
| Q1 24 | 89.2% | 89.0% |
| Q4 25 | -82.2% | — | ||
| Q3 25 | -102.6% | — | ||
| Q2 25 | -93.4% | — | ||
| Q1 25 | -143.7% | — | ||
| Q4 24 | -98.6% | — | ||
| Q3 24 | -132.0% | — | ||
| Q2 24 | -139.2% | — | ||
| Q1 24 | -538.7% | — |
| Q4 25 | -83.0% | 10.0% | ||
| Q3 25 | -103.1% | 23.3% | ||
| Q2 25 | -96.1% | 17.6% | ||
| Q1 25 | -151.4% | 16.4% | ||
| Q4 24 | -103.6% | 23.9% | ||
| Q3 24 | -131.2% | 25.9% | ||
| Q2 24 | -110.9% | 10.6% | ||
| Q1 24 | -544.4% | 29.6% |
| Q4 25 | $-0.73 | $0.10 | ||
| Q3 25 | $-0.82 | $0.21 | ||
| Q2 25 | $-0.75 | $0.15 | ||
| Q1 25 | $-0.81 | $0.14 | ||
| Q4 24 | $-0.71 | $0.20 | ||
| Q3 24 | $-0.73 | $0.21 | ||
| Q2 24 | $-0.55 | $0.08 | ||
| Q1 24 | $-2.35 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $388.9M | $32.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $139.1M | $1.3B |
| Total Assets | $480.2M | $2.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $388.9M | $32.3M | ||
| Q3 25 | $416.1M | $27.7M | ||
| Q2 25 | $291.0M | $24.8M | ||
| Q1 25 | $314.5M | $30.5M | ||
| Q4 24 | $320.6M | $39.8M | ||
| Q3 24 | $298.4M | $28.6M | ||
| Q2 24 | $319.1M | $87.0M | ||
| Q1 24 | $201.2M | $90.2M |
| Q4 25 | $139.1M | $1.3B | ||
| Q3 25 | $148.8M | $1.3B | ||
| Q2 25 | $-11.9M | $1.4B | ||
| Q1 25 | $18.9M | $1.4B | ||
| Q4 24 | $21.7M | $1.4B | ||
| Q3 24 | $11.2M | $1.4B | ||
| Q2 24 | $39.3M | $1.5B | ||
| Q1 24 | $61.6M | $1.5B |
| Q4 25 | $480.2M | $2.1B | ||
| Q3 25 | $506.9M | $2.1B | ||
| Q2 25 | $372.7M | $2.0B | ||
| Q1 25 | $386.7M | $2.0B | ||
| Q4 24 | $392.3M | $2.0B | ||
| Q3 24 | $363.6M | $2.0B | ||
| Q2 24 | $381.8M | $2.1B | ||
| Q1 24 | $258.7M | $2.1B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-25.4M | $119.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 23.76× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-25.4M | $119.1M | ||
| Q3 25 | $-26.6M | $30.0M | ||
| Q2 25 | $-23.3M | $31.9M | ||
| Q1 25 | $-40.4M | $24.1M | ||
| Q4 24 | $-18.8M | $132.8M | ||
| Q3 24 | $-25.2M | $29.1M | ||
| Q2 24 | $-29.1M | $31.6M | ||
| Q1 24 | $-40.7M | $36.6M |
| Q4 25 | — | 23.76× | ||
| Q3 25 | — | 2.59× | ||
| Q2 25 | — | 3.71× | ||
| Q1 25 | — | 3.06× | ||
| Q4 24 | — | 11.95× | ||
| Q3 24 | — | 2.43× | ||
| Q2 24 | — | 6.84× | ||
| Q1 24 | — | 2.44× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
